Ami Fadia, an analyst from Needham, reiterated the Buy rating on Praxis Precision Medicines. The associated price target remains the same with $250.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Ami Fadia has given his Buy rating due to a combination of factors related to Praxis Precision Medicines’ recent developments. The company received positive feedback from the FDA regarding its relutrigine program, which is a promising sign for the future of their drug development. The FDA’s agreement on Praxis’ proposed interim analysis for the EMBOLD Cohort 2 study as the basis for an NDA submission in early 2026 underscores the potential of their ongoing research.
A key factor in the Buy rating is the strong efficacy data from the EMBOLD Cohort 1 study, which has been updated to better account for baseline variability in seizures. The interim analysis, which is expected in the fourth quarter of 2025, will involve a significant portion of the study’s participants and is anticipated to be successful. The management’s confidence in the study’s success, as well as the study being overpowered, further supports the positive outlook for Praxis Precision Medicines.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $232.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRAX in relation to earlier this year.